ReviewLa Radiologia medica2025
Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.
Review in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review.Japanese journal of radiology · 2026Review
- JJR-TOP GUN Phase 2: broadening the scope through advances in radiology and interdisciplinary innovation.Japanese journal of radiology · 2026Article
- Artificial intelligence for pediatric neuroimaging.Pediatric radiology · 2026Review
- Conventional MRI/CT for differentiation of IDH-mutant adult-type diffuse gliomas: revisited with a new imaging feature "scFLAIR-D".Japanese journal of radiology · 2026Article
- A PIK3CA and NF1 expression-based prognostic signature derived from Mendelian randomization identifies causal immune-regulatory determinants of glioblastoma outcomes.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Recent advances in molecular genetics have revolutionized the classification of pediatric-type high-grade gliomas in the 2021 World Health Organization central nervous system tumor classification. This narrative review synthesizes current evidence on the following four tumor types: diffuse midline glioma, H3 K27-altered; diffuse hemispheric glioma, H3 G34-mutant; diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; and infant-type hemispheric glioma. We conducted a comprehensive literature search for articles published through January 2025. For each tumor type, we analyze characteristic clinical presentations, molecular alterations, conventional and advanced magnetic resonance imaging features, radiological-molecular correlations, and current therapeutic approaches. Emerging radiogenomic approaches utilizing artificial intelligence, including radiomics and deep learning, show promise in identifying imaging biomarkers that correlate with molecular features. This review highlights the importance of integrating radiological and molecular data for accurate diagnosis and treatment planning, while acknowledging limitations in current methodologies and the need for prospective validation in larger cohorts. Understanding these correlations is crucial for advancing personalized treatment strategies for these challenging tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.